WASHINGTON, Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced ...

UBS analyst Kevin Caliendo lowered the firm’s price target on Evolent Health (EVH) to $14 from $27 and keeps a Buy rating on the shares. The company’s investor presentation was “less ...

TD Cowen analyst Charles Rhyee assigned a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $14.00. Charles Rhyee has given his Buy rating due to a combination ...

Evolent Health (NYSE:EVH) rose 1.3% after activist investor Engaged Capital reached a cooperation agreement with the healthcare services company. Evolent (NYSE:EVH) will add Brendan Springstubb to ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

WASHINGTON - Evolent Health, Inc. (NYSE: EVH), a health outcomes company currently trading near its 52-week low at $10.21, today announced the appointment of Richard "Rick" Jelinek as its new ...

Evolent Health, Inc. has a 52 week low of $9.56 and a 52 week high of $35.00. The firm’s fifty day moving average is $11.04 and its 200 day moving average is $19.69.

Evolent Health, Inc. (NYSE: NYSE:EVH), a provider of healthcare delivery and payment solutions, has been navigating a complex landscape of opportunities and challenges in recent months. Trading ...

Evolent Health, Inc. has a 1 year low of $9.74 and a 1 year high of $35.00. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -11.21 and a beta of 1.45.

The FDA's accelerated approval of aducanumab led to controversy and a congressional investigation, highlighting issues in the approval process. The HHS OIG report found deviations in 3 out of 24 ...

Evolent Health, Inc. (NYSE: NYSE:EVH), a provider of healthcare delivery and payment solutions, has been navigating a complex landscape of opportunities and challenges in recent months. Trading near ...